<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163760</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0706</org_study_id>
    <secondary_id>PRO-518</secondary_id>
    <nct_id>NCT01163760</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Two Daily Disposable Contact Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore Polytechnic University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Visioncare Research Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the clinical performance of two daily disposable contact lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lens Comfort</measure>
    <time_frame>1-week follow-up</time_frame>
    <description>Lens comfort was evaluated via the subjective question: &quot;How comfortable did your eyes feel at the end of the day when wearing the contact lenses you were provided?&quot; (excellent/very good=5...very good=3...Poor=0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comfort Throughout the Whole Day</measure>
    <time_frame>1-week follow-up</time_frame>
    <description>Comfort throughout the day was evaluated via subjective question: &quot;Comfort throughout the whole day&quot; and is reported as an aggregate of &quot;Agree Strongly and Agree Somewhat&quot;.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comfort While Working on Computer</measure>
    <time_frame>1-week-follow-up</time_frame>
    <description>Comfort throughout the day was evaluated via subjective question: &quot;Comfort while working on computer&quot; and is reported as an aggregate of &quot;Agree Strongly and Agree Somewhat&quot;.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>etafilcon A / ocufilcon D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>etafilcon A contact lens worn first daily disposable , ocufilcon D contact lens worn second daily disposable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oculfilcon D / etafilcon A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ocufilcon D contact lens worn first, etafilcon A contact lens worn second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ocufilcon D / ocufilcon D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ocufilcon D contact lens worn first and second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A / etafilcon A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>etafilcon A contact lens worn first and second</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A</intervention_name>
    <description>daily disposable contact lens</description>
    <arm_group_label>etafilcon A / ocufilcon D</arm_group_label>
    <arm_group_label>oculfilcon D / etafilcon A</arm_group_label>
    <arm_group_label>etafilcon A / etafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ocufilcon D</intervention_name>
    <description>daily disposable contact lens</description>
    <arm_group_label>etafilcon A / ocufilcon D</arm_group_label>
    <arm_group_label>oculfilcon D / etafilcon A</arm_group_label>
    <arm_group_label>ocufilcon D / ocufilcon D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be between 21 and 39 years of age.

          -  Signed Written Informed Consent and Investigator to record this on Case Report Form
             (CRF) in appropriate space.

          -  Be existing (i.e. successfully worn for 1-month prior to the study) soft contact lens
             wearers (no extended wear in the last 3 months, but silicone hydrogels in daily wear
             are allowed).

          -  Require a visual correction in both eyes (monovision allowed but no monofit).

          -  Have a contact lens spherical distance requirement between -1.00D and -6.00D in both
             eyes.

          -  Astigmatism of 1.00D or less in both eyes.

          -  Be able to wear the lens powers available for this study.

          -  Be correctable to a visual acuity of 20/30 or better in each eye.

          -  Have normal eyes with no evidence of abnormality or disease. For the purposes of this
             study a normal eye is defined as one having:

               -  No amblyopia.

               -  No evidence of lid abnormality or infection.

               -  No conjunctival abnormality or infection.

               -  No clinically significant slit lamp findings (i.e. edema, staining, scarring,
                  vascularisation, infiltrates or abnormal opacities).

               -  No other active ocular disease.

        Exclusion Criteria:

          -  Requires concurrent ocular medication.

          -  Any systemic illness which would contraindicate lens wear or the medical treatment of
             which would affect vision or successful lens wear.

          -  Clinically significant (Grade 3 or 4) corneal edema, corneal vascularisation, corneal
             staining, tarsal abnormalities, bulbar injection or any other abnormality of the
             cornea that would contraindicate contact lens wear.

          -  Diabetic.

          -  Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease
             (e.g., HIV).

          -  Extended lens wear in last 3 months.

          -  PMMA or RGP lens wear in the previous 8 weeks.

          -  Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately
             prior to enrollment for this study.

          -  Abnormal lacrimal secretions.

          -  Pre-existing ocular irritation that would preclude contact lens fitting.

          -  Keratoconus or other corneal irregularity.

          -  Pregnancy, lactating or planning a pregnancy at the time of enrollment.

          -  Participation in any concurrent clinical trial or in last 60 days.&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <results_first_submitted>October 1, 2008</results_first_submitted>
  <results_first_submitted_qc>June 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2010</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 50 subjects enrolled in this single site study, located at Singapore University.</recruitment_details>
      <pre_assignment_details>There were 50 patients enrolled and randomized, and 50 patients completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etafilcon A First, Then Ocufilcon D</title>
          <description>etafilcon A contact lenses worn first,ocufilcon D contact lenses worn second</description>
        </group>
        <group group_id="P2">
          <title>Ocufilcon D First, Then Etafilcon A</title>
          <description>ocufilcon D contact lenses worn first,etafilcon A contact lenses worn second.</description>
        </group>
        <group group_id="P3">
          <title>Etafilcon A First, Then Etafilcon A</title>
          <description>etafilcon A contact lenses worn for both periods.</description>
        </group>
        <group group_id="P4">
          <title>Ocufilcon D First, Then Ocufilcon D</title>
          <description>Ocufilcon D contact lenses worn for both periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Fit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (Follow-up)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 (Fit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4 (Follow-up)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Total number of completed participants are included in baseline measurements.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lens Comfort</title>
        <description>Lens comfort was evaluated via the subjective question: &quot;How comfortable did your eyes feel at the end of the day when wearing the contact lenses you were provided?&quot; (excellent/very good=5...very good=3...Poor=0)</description>
        <time_frame>1-week follow-up</time_frame>
        <population>Subjects analyzed were those who were enrolled, randomized, and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>etafilcon A contact lenses worn in either the first or second period.</description>
          </group>
          <group group_id="O2">
            <title>Ocufilcon D</title>
            <description>ocufilcon D contact lenses worn in either the first or second period.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Comfort</title>
          <description>Lens comfort was evaluated via the subjective question: &quot;How comfortable did your eyes feel at the end of the day when wearing the contact lenses you were provided?&quot; (excellent/very good=5...very good=3...Poor=0)</description>
          <population>Subjects analyzed were those who were enrolled, randomized, and completed the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="0.98"/>
                    <measurement group_id="O2" value="3.00" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comfort Throughout the Whole Day</title>
        <description>Comfort throughout the day was evaluated via subjective question: &quot;Comfort throughout the whole day&quot; and is reported as an aggregate of &quot;Agree Strongly and Agree Somewhat&quot;.</description>
        <time_frame>1-week follow-up</time_frame>
        <population>Subjects analyzed were those enrolled, randomized, and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>etafilcon A contact lenses worn in either the first or second period.</description>
          </group>
          <group group_id="O2">
            <title>Ocufilcon D</title>
            <description>ocufilcon D contact lenses worn in either the first or second period.</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort Throughout the Whole Day</title>
          <description>Comfort throughout the day was evaluated via subjective question: &quot;Comfort throughout the whole day&quot; and is reported as an aggregate of &quot;Agree Strongly and Agree Somewhat&quot;.</description>
          <population>Subjects analyzed were those enrolled, randomized, and completed the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Comfort While Working on Computer</title>
        <description>Comfort throughout the day was evaluated via subjective question: &quot;Comfort while working on computer&quot; and is reported as an aggregate of &quot;Agree Strongly and Agree Somewhat&quot;.</description>
        <time_frame>1-week-follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>etafilcon A contact lenses worn in either the first or second period.</description>
          </group>
          <group group_id="O2">
            <title>Ocufilcon D</title>
            <description>ocufilcon D contact lenses worn in either the first or second period.</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort While Working on Computer</title>
          <description>Comfort throughout the day was evaluated via subjective question: &quot;Comfort while working on computer&quot; and is reported as an aggregate of &quot;Agree Strongly and Agree Somewhat&quot;.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etafilcon A/ Ocufilcon D</title>
          <description>etafilcon A contact lenses worn first,ocufilcon D contact lenses worn second</description>
        </group>
        <group group_id="E2">
          <title>Ocufilcon D / Etafilcon A</title>
          <description>ocufilcon D contact lenses worn first,etafilcon A contact lenses worn second.</description>
        </group>
        <group group_id="E3">
          <title>Etafilcon A/ Etafilcon A</title>
          <description>etafilcon A contact lenses worn first and second period.</description>
        </group>
        <group group_id="E4">
          <title>Oculfilcon D / Ocufilcon D</title>
          <description>ocufilcon D contact lenses worn first and second period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The integrity of the subject reported data is suspect and not reflective of lens’ performance due to a significant protocol deviation. Upon completion of the study it was found that subjects were unmasked and their data should be considered biased.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kurt Moody OD, FAAO</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-3088</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

